ED drugs sold 3.5 billion, and domestic brands won the championship for the first time!

Pfizer's sildenafil citrate orally disintegrating tablets were declared clinically in China in 2013, and they were imported into the market in 2017.
They were finally approved to enter the Chinese market at the end of 2019, giving patients with swallowing disorders or difficulties, and inconvenient water access for erections.
New choice of medication for patients with dysfunction
.
The news pointed out that the original research drug entered JD Health after it was listed, and at the same time it was first launched on the JD Pharmacy online.
The “renewal of old drugs” is also considered by the industry as a change after the adoption of countries that have failed the standard
.

However, the battlefield just developed by Pfizer will also usher in new changes.
In September 2020, Kelun was the first to declare the 4 types of imitation listing of Sildenafil Citrate Orally Disintegrating Tablets and is currently under review and approval
.
Kelun won the first domestic imitation of vardenafil hydrochloride tablets in 2020.
If sildenafil citrate orally disintegrating tablets can be successfully approved, it will also become the first domestic imitation, and at the same time contribute to the company's ED drug camp.

.

According to data from Meinenet, Kelun declared and approved the clinical application of a new drug for sildenafil citrate oral dissolving film in 2021.
This product is Kelun’s first oral instant dissolving film and is expected to become the company’s in this field.
The first approved product
.

Conclusion

In recent years, with the expiration of the patents of the original research drugs, domestic generic drugs have sprung up.
Driven by consistency evaluation and the country's centralized procurement, domestic brands have become dazzling new stars in the market
.
Baiyunshan's Jin Ge was approved earlier, and after years of hard work, it eventually became the first brand
.
In the next period of time, the old varieties will usher in a blowout period for the approval of generic drugs, and there is no doubt that market competition will become more intense
.
Leading pharmaceutical companies with strong R&D capabilities such as Qilu and Kelun have gradually set their sights on improved new drugs.
With the continuous promotion of "innovative %20 imitation", China's ED drug market will flourish
.

Source: Mynet database, company annual report, etc.

The review data statistics are as of July 13, if there are any errors or omissions, please correct me
.